Suppr超能文献

双相障碍的药物治疗疗效:WPA 药物精神医学分会报告。

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

机构信息

3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, 6 Odysseos str./1st Parodos Ampelonon str., Pylaia, Thessaloniki, Greece.

出版信息

Eur Arch Psychiatry Clin Neurosci. 2012 Jun;262 Suppl 1:1-48. doi: 10.1007/s00406-012-0323-x.

Abstract

The current statement is a systematic review of the available data concerning the efficacy of medication treatment of bipolar disorder (BP). A systematic MEDLINE search was made concerning the treatment of BP (RCTs) with the names of treatment options as keywords. The search was updated on 10 March 2012. The literature suggests that lithium, first and second generation antipsychotics and valproate and carbamazepine are efficacious in the treatment of acute mania. Quetiapine and the olanzapine-fluoxetine combination are also efficacious for treating bipolar depression. Antidepressants should only be used in combination with an antimanic agent, because they can induce switching to mania/hypomania/mixed states/rapid cycling when utilized as monotherapy. Lithium, olanzapine, quetiapine and aripiprazole are efficacious during the maintenance phase. Lamotrigine is efficacious in the prevention of depression, and it remains to be clarified whether it is also efficacious for mania. There is some evidence on the efficacy of psychosocial interventions as an adjunctive treatment to medication. Electroconvulsive therapy is an option for refractory patients. In acute manic patients who are partial responders to lithium/valproate/carbamazepine, adding an antipsychotic is a reasonable choice. The combination with best data in acute bipolar depression is lithium plus lamotrigine. Patients stabilized on combination treatment might do worse if shifted to monotherapy during maintenance, and patients could benefit with add-on treatment with olanzapine, valproate, an antidepressant, or lamotrigine, depending on the index acute phase. A variety of treatment options for BP are available today, but still unmet needs are huge. Combination therapy may improve the treatment outcome but it also carries more side-effect burden. Further research is necessary as well as the development of better guidelines and algorithms for the step-by-step rational treatment.

摘要

目前的声明是对有关双相情感障碍(BP)药物治疗疗效的现有数据进行的系统评价。使用治疗方法的名称作为关键字对 BP(RCT)的治疗进行了系统的 MEDLINE 搜索。搜索于 2012 年 3 月 10 日进行了更新。文献表明,锂、第一代和第二代抗精神病药以及丙戊酸和卡马西平在治疗急性躁狂症方面是有效的。喹硫平和奥氮平-氟西汀联合治疗也可有效治疗双相抑郁症。抗抑郁药只能与抗躁狂药联合使用,因为它们在单药治疗时可能会导致躁狂/轻躁狂/混合状态/快速循环转换。锂、奥氮平、喹硫平和阿立哌唑在维持期有效。拉莫三嗪可有效预防抑郁,但尚不清楚它是否对躁狂也有效。有一些证据表明心理社会干预作为药物辅助治疗的有效性。电惊厥治疗是难治性患者的一种选择。在对锂/丙戊酸/卡马西平部分反应的急性躁狂患者中,添加一种抗精神病药是合理的选择。在急性双相抑郁症中,数据最好的联合治疗是锂加拉莫三嗪。在维持期从联合治疗转为单药治疗的患者可能会恶化,而根据指数急性阶段,添加奥氮平、丙戊酸、抗抑郁药或拉莫三嗪的附加治疗可能会使患者受益。目前有多种 BP 治疗选择,但仍有巨大的未满足需求。联合治疗可能会改善治疗效果,但也会带来更多的副作用负担。还需要进一步研究,并制定更好的指南和算法,以逐步进行合理治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验